Erythema abigne, commonly known as sunburn, is one of the most common skin conditions. It is caused by overexposure to ultraviolet (UV) radiation from the sun or tanning beds. It is characterized by redness, swelling, and pain in the skin. Erythema abigne is especially common in fair-skinned individuals and those with a family history of skin cancer. It is important for doctors to be aware of the signs and symptoms of this condition and to educate their patients on how to prevent it.
Erythema abigne is an inflammatory skin condition that is caused by overexposure to ultraviolet (UV) radiation from the sun or tanning beds. It is characterized by redness, swelling, and pain in the skin. It can range from mild to severe, depending on the amount of exposure to UV radiation and the individual's skin type. In some cases, blisters may form and the skin may become itchy, scaly, or dry. Erythema abigne typically resolves within a few days to weeks, but it can cause permanent damage to the skin if left untreated.
Erythema abigne is caused by overexposure to ultraviolet (UV) radiation from the sun or tanning beds. UV radiation is a type of energy from the sun that is invisible to the human eye. It is divided into three types: UVA, UVB, and UVC. UVA and UVB rays are the most common causes of sunburn. UVA rays are the most damaging and penetrate deeper into the skin, while UVB rays are less damaging and cause more superficial damage.
Anyone can develop erythema abigne, but some people are more at risk than others. People with fair skin, light-colored eyes, and red or blond hair are more likely to experience sunburn. People with a family history of skin cancer are also at an increased risk. Additionally, people who spend a lot of time outdoors without adequate sun protection are more likely to develop erythema abigne.
The most common signs and symptoms of erythema abigne are redness, swelling, and pain in the skin. The skin may also feel warm to the touch and become itchy or scaly. In some cases, blisters may form. The skin may also become dry and peel after the sunburn has healed.
Erythema abigne is usually diagnosed based on the patient's history and physical examination. A doctor may also perform a skin biopsy to confirm the diagnosis. A skin biopsy involves taking a small sample of the affected skin and examining it under a microscope. This can help determine the extent of the damage and rule out other possible causes of the symptoms.
The primary treatment for erythema abigne is to protect the skin from further UV radiation exposure. This can be done by avoiding direct sunlight, wearing protective clothing, and using sunscreen with an SPF of 30 or higher. In addition, over-the-counter pain relievers such as ibuprofen or acetaminophen can help reduce pain and swelling. For severe cases, a doctor may prescribe a topical or oral steroid to reduce inflammation.
The best way to prevent erythema abigne is to protect the skin from UV radiation. This can be done by avoiding direct sunlight, wearing protective clothing, and using sunscreen with an SPF of 30 or higher.
Erythema abigne is a common skin condition caused by overexposure to ultraviolet (UV) radiation from the sun or tanning beds. It is characterized by redness, swelling,
1.
Advances in "next generation" photoactive cancer therapy
2.
Multidrug Regimen Could Change Treatment Landscape for Relapsed/Refractory DLBCL
3.
The American College of Physicians updated its recommendations for colorectal cancer screening.
4.
Optimizing Sequencing of BCMA-Directed Therapies in Myeloma
5.
According to a study, patients with ovarian cancer who undergo aggressive surgery have a 70% lower chance of dying.
1.
Quality of Life Using Precision Functional Recovery After Organ-Preserving Interventions
2.
Cancer Memory: A Persistent Threat to Tumor Recurrence and Metastasis
3.
Neoadjuvant Abraxane Chemotherapy Combined with Neutrophil Cytopharmaceuticals and Radiotherapy
4.
Modern Developments in Oncology for Specialists
5.
Can We Repurpose BV-CHP for Better Outcomes in Peripheral T-Cell Lymphoma?
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
1.
Breaking Down PALOMA-2: How CDK4/6 Inhibitors Redefined Treatment for HR+/HER2- Metastatic Breast Cancer
2.
Role of Nimotuzumab in Management of Nasopharyngeal Cancer
3.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
4.
Evolving Space of First-Line Treatment for Urothelial Carcinoma- Case Discussion
5.
Navigating the Complexities of Ph Negative ALL - Part XII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation